相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
Encouse B. Golden et al.
LANCET ONCOLOGY (2015)
Radiotherapy and Toll-Like Receptor Agonists
Aurelien Marabelle et al.
SEMINARS IN RADIATION ONCOLOGY (2015)
Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
David J. DiLillo et al.
CANCER IMMUNOLOGY RESEARCH (2015)
European cancer mortality predictions for the year 2014
M. Malvezzi et al.
ANNALS OF ONCOLOGY (2014)
Intratumoral Immunization: A New Paradigm for Cancer Therapy
Aurelien Marabelle et al.
CLINICAL CANCER RESEARCH (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Dmitriy Zamarin et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Role of Chemoattractant Receptors in Shaping the Tumor Microenvironment
Jiamin Zhou et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Vaccines for Cancer Prevention: A Practical and Feasible Approach to the Cancer Epidemic
Olivera J. Finn
CANCER IMMUNOLOGY RESEARCH (2014)
New insights into the mechanism of action of immune checkpoint antibodies
Aurelien Marabelle et al.
ONCOIMMUNOLOGY (2014)
The immune landscape of human tumors Implications for cancer immunotherapy
Gabriela Bindea et al.
ONCOIMMUNOLOGY (2014)
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
Elena Garcia-Martinez et al.
BREAST CANCER RESEARCH (2014)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer
Wilber Quispe-Tintaya et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Youn H. Kim et al.
BLOOD (2012)
Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer
Lauren J. Bayne et al.
CANCER CELL (2012)
Systemic treatment of advanced pancreatic cancer
Volker Heinemann et al.
CANCER TREATMENT REVIEWS (2012)
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
Hedy Lee Kindler et al.
INVESTIGATIONAL NEW DRUGS (2012)
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study
David Olmos et al.
LANCET ONCOLOGY (2012)
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
Robert W. Ross et al.
LANCET ONCOLOGY (2012)
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Andrew V. Biankin et al.
NATURE (2012)
Abscopal Effect in a Patient with Melanoma
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Chen Sun et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Potential targets for pancreatic cancer immunotherapeutics
Lindzy F. Dodson et al.
IMMUNOTHERAPY (2011)
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
Synne Weden et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Differential effects of Paclitaxel on dendritic cell function
Justin John et al.
BMC IMMUNOLOGY (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
Lukas W. Pfannenstiel et al.
CELLULAR IMMUNOLOGY (2010)
Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4
Scott Wilkie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Hedy Lee Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Joshua D. Brody et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Richard E. Royal et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Pancreatic Cancer
Manuel Hidalgo
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α
Matthew Kraman et al.
SCIENCE (2010)
Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice
Lin Yuan et al.
VACCINE (2010)
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
Roch Houot et al.
BLOOD (2009)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Immunosurveillance of pancreatic adenocarcinoma: Insights from genetically engineered mouse models of cancer
Carolyn E. Clark et al.
CANCER LETTERS (2009)
Circulating Mesothelin Protein and Cellular Antimesothelin Immunity in Patients with Pancreatic Cancer
Fabian Mc. Johnston et al.
CLINICAL CANCER RESEARCH (2009)
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
Yangbing Zhao et al.
JOURNAL OF IMMUNOLOGY (2009)
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
Carmine Carpenito et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
RhoC a new target for therapeutic vaccination against metastatic cancer
Lynn Wenandy et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Immunogenicity of the hTERT540-548 peptide in cancer
Lynn Wenandy et al.
CLINICAL CANCER RESEARCH (2008)
The anticancer immune response: indispensable for therapeutic success?
Laurence Zitvogel et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Tumour immunity: effector response to tumour and role of the microenvironment
Alberto Mantovani et al.
LANCET (2008)
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer
Stefan Boeck et al.
ANTI-CANCER DRUGS (2007)
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function
Jeremy B. Swann et al.
JOURNAL OF IMMUNOLOGY (2007)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
Interferons, immunity and cancer immunoediting
Gavin P. Dunn et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin
Marion Wobser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions
Nobuyoshi Hiraoka et al.
CLINICAL CANCER RESEARCH (2006)
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer
B Kubuschok et al.
CLINICAL CANCER RESEARCH (2006)
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro
P Correale et al.
JOURNAL OF IMMUNOLOGY (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2004)
分享论文
